The 7th Annual Biosimilars Conference
Hear from over 20 Expert Leaders in the Biosimilar Field
With over 15 new speakers confirmed for Informa's 2010 Biosimilars Conference, this year's event will be an unmissable opportunity to update your knowledge on this dynamic and important market with some of the field's best experts.
Highlights of Biosimilars 2010
- Explore the latest developments with biobetters and read more
- Revisit the EU Market. Learn what read more
- Discover recent developments with biosimilar mAbs. Hear from read more
- Update your knowledge on advancements in read more
- Analyse the strategies used by F Hoffmann- La Roche for read more
- Ascertain what the physician’s perception is read more
- Familiarise yourself with patent law strategies and read more
Expert Speaker Pannel
Expert Speaker Pannel
Dr Jay Siegel
Chief Biotechnology Officer
Johnson & Johnson
|
Mateja Urlep
Founder & CEO
TikhePharma
|
Dr Werner Kliche
Associate Director
Boehringer Ingelheim Pharma
|
Richard Dicicco
Chairman
Harvest Moon Pharmaceuticals
|
Dr Christian Clauss
Senior Consultant
Hisut SA Ltd
|
Dr Anton Haselbeck
Head of New Technologies
Roche Pharma Research
|
Dr Anshuman Patwardhan
Senior Director
Dr Reddy's
|
Dr Keith Watson
Principle Consultant
PAREXEL
|
..
Media Partners
..
..
..
..
Sponsors
..
..
..
Where and When?
08 Jun 2010 - 09 Jun 2010
Pullman Hotel, Cologne, Germany
Speakers at Biosimilars 2010
Cecil Nick, PAREXEL, UK
Mateja Urlep, TikhePharma, (Formerly Sandoz), Slovenia
Robin Thorpe, NIBSC, UK
Anne Cook, MHRA, UK
Stanley SS Hong, Celltrion, South Korea
Anshuman Patwardhan, Dr Reddy's Laboratories, India
Lorna Brazell, Bird & Bird LLP, UK Richard Dicicco, Harvest Moon Pharmaceuticals, USA
Anton Haselbeck, Roche Pharma Research, Germany
Sven Kronenberg, F. Hoffmann-La Roche Ltd, Switzerland
Michael Malecki, Decision Resources, USA
Liz Fuller, Wragge and Co., UK
Keith Watson, PAREXEL, UK (Formerly MHRA)
William Haddad, Biogenerics, USA
Werner Kliche, Boehringer Ingelheim Pharma, Germany
Jay Siegel, Johnson & Johnson, USA
Fernando de Mora, Salupharma Biosimilars SA, Universidad Autónoma de Barcelona, Spain
Tuesday 8 June: Evening Seminar
Fast Followers, Differentiated Biosimilars, BioBetters or NBEs – Which Strategy is Best for Which Markets?
Gain an understanding of
-
how biobetters and differentiated biosimilars are
viable alternatives to biosimilars for regulated markets -
how copy biopharmaceuticals
can generate profits to sustain research for NBEs -
and how small molecules are threatening fast followers in regulated markets
Led by Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals, USA
Sponsors
Poll
What area of the EU’s current regulatory framework on biosimilars is most in need of reform?
Please select an answer
Reviews
"This biosimilars conference was Bio Better than others in this field"
"Very interesting two days covering several aspects (technical, regulatory, legal) of the biosimilar topic!"
"Interesting and informative"
